Vineet Laboratories Ltd

Vineet Laboratories Ltd has announced that its Board of Directors will convene on August 25, 2026. The primary agenda item for this meeting is to consider and approve the Audited Standalone Financial Results for the Fourth Quarter and the Financial Year ended March 31, 2026. Concurrently, the company has confirmed that the trading window for its equity shares, which was closed for designated persons and connected individuals, will remain shut until 48 hours after the declaration of these financial results, in compliance with SEBI regulations.

Vineet Laboratories Ltd has submitted its Monitoring Agency Report for the quarter ended June 30, 2026. The report, issued by CRISIL Ratings Limited, details the utilization of funds raised through the company's Rights Issue. CRISIL, appointed as the Monitoring Agency, has provided its assessment as per SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018. The report confirms that there were no deviations from the stated objects of the issue and no specific range of deviation was applicable. The filing includes a declaration from CRISIL stating the report is based on information provided by the issuer and believed to be accurate, while clarifying that it does not constitute an audit or independent verification.

Vineet Laboratories Ltd announced that Mr. Gaddam Venkata Ramana has ceased to hold the office of Managing Director effective July 21, 2026. He will continue to serve as a Director of the company. This change is in accordance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Mr. Ramana is a promoter and promoter group member and holds 4,71,000 equity shares.

Vineet Laboratories Ltd has announced the appointment of Rajesh Kumar Kathulla as an Additional Director in the Executive Category. This appointment is effective from June 11, 2026, and is subject to shareholder approval. Mr. Kathulla brings over a decade of experience as an entrepreneur and corporate director, with a focus on promoter-driven ventures in diverse sectors including renewable energy, organic agriculture, lifestyle, and media. He is not related to any existing Directors or Key Managerial Personnel and Promoters of the company. He holds 50,254 equity shares in the company.

Vineet Laboratories Ltd has announced the deferment of its Board Meeting, originally scheduled for July 15, 2026. The meeting was intended to consider and approve the Audited Financial Results for the Financial Year ended March 31, 2026. The deferment is due to unavoidable circumstances. The company will issue a fresh notice with the revised date, time, and venue for the meeting in due course, adhering to SEBI Listing Regulations.

Vineet Laboratories Ltd has announced that its Board of Directors will convene on July 15, 2026. The primary agenda item is to consider and approve the audited standalone financial results for the fourth quarter and the full financial year ended March 31, 2026. Concurrently, the company has confirmed that the trading window for designated persons will remain closed until 48 hours after the declaration of these financial results, in compliance with SEBI regulations.

Vineet Laboratories Ltd's board meeting on May 30, 2026, deferred the consideration of the audited standalone financial results for the quarter and financial year ended March 31, 2026, as the Audit Committee did not consider and recommend them. The company will intimate the revised dates for the Audit Committee Meeting and Board Meeting to the Stock Exchange(s) in due course. The trading window, which was closed from April 1, 2026, will remain closed until 48 hours after the declaration of the financial results.

Vineet Laboratories Ltd has scheduled a Board of Directors meeting on May 30, 2026, to consider and approve the Audited Standalone Financial Results for the fourth quarter and financial year ended March 31, 2026. The trading window for dealing in the company's equity shares has been closed from April 01, 2026, until 48 hours after the announcement of the financial results, in compliance with SEBI regulations.

Vineet Laboratories Ltd has released the Monitoring Agency Report issued by Crisil Ratings Limited for the quarter ended March 31, 2026, pertaining to the utilization of funds raised through the Rights Issue. Crisil's report indicates that the proceeds have been utilized towards repayment of loans, purchase of equipment, working capital requirements, and issue expenses. The report declares no deviations from the stated objectives in the offer document.

Vineet Laboratories Ltd has announced the closure of its trading window from 01st April, 2026 till 48 hours after the announcement of Standalone Audited Financial results for the Fourth Quarter and Financial year ending on 31st March, 2026. This closure is in accordance with the SEBI (Prohibition of Insider Trading) Regulations, 2015 and the Company's Code of Conduct for regulating, monitoring, and reporting trading by Insiders and Code of Practices and Procedures for fair disclosure of Unpublished Price Sensitive Information. The PAN of all the Designated Persons (‘DPs”) and their immediate relatives have been frozen during the period of trading window closure. The date of the Board Meeting for declaration of the Standalone Audited Financial results will be intimated in due course.